NEWS  

21 JUN 2010  Preliminary Results for the Year Ended 31 December 2009

ABI continues to expand unit sales of its core products and progress new product development.  ABI believes that the scale of opportunity for the PIFA® Heparin/PF4 Rapid Assay, BreathScan® PRO, Breath Ketone “Check”™ and Breath PulmoHealth “Check”™ will be the transformational, long-term drivers of growth and value.

14 JUN 2010   PIFA^® Heparin/PF4 Rapid Assay USA Distribution Agreement - Fisher HealthCare

ABI has announced the inception of a major distribution relationship Fisher HealthCare in the USA for the PIFA® Heparin/PF4 Rapid Assay (PIFA HPF4) and related products. Fisher HealthCare is one of America’s leading healthcare product channels. The addition of Fisher HealthCare’s resources will expose almost 100% of hospitals to ABI’s product offerings and more than double the number of sales personnel marketing the PIFA HPF4 test in the USA.

17 MAR 2010  ABI Licenses BreathScan^® Rights for UK & Republic of Ireland

The Company has licensed the exclusive sales, marketing, and distribution rights for the BreathScan product line in the UK and Republic of Ireland, to BreathScan International Ltd ("BIL") for a period of five years.  The London-based BIL will also have a non-exclusive right to develop opportunities internationally, outside of North America. The agreement demonstrates ABI's dedication to establishing a more targeted, strategic focus on BreathScan which should also accelerate the adoption of the BreathScan line worldwide.

16 MAR 2010  Clinical Study Data - PIFA^® Heparin/PF-4 Rapid Assay

Researchers at the University of Miami/Jackson Memorial Hospital presented data supporting the clinical utility of ABI's PIFA Heparin/PF-4 Rapid Assay at the 30th International Symposium of Intensive Care and Emergency Medicine ("ISICEM") last week in Brussels, Belgium.  Authors have concluded, from the interim data obtained thus far, that ABI's unique, patented PIFA assay can quickly rule out the presence of HIT, thus preventing a patient from receiving unnecessary alternative anticoagulation therapy, and assisting the physician in the rapid diagnosis of the patient's condition. 

Government & Defense Procurement Information

All Products Proudly Manufactured in the USA

For additional information, please call +1 856 848 2116 or 1.800.451.TEST.